and no evidence of tumour on MRI and have received DA treatment for at least 2 years. 4 Nevertheless, the probability of maintenance of remission is low with a meta-analysis showing persisting normoprolactinaemia after DA withdrawal in 21% of micro-and 16% of macroprolactinomas 5 ; notably, the recurrences are most likely to occur within a year after stopping DA therapy. 6, 7 The Endocrine Society USA guidelines also advise consideration of discontinuation of DA therapy in women with microprolactinoma when menopause occurs, with continuing surveillance. 4 This approach seems desirable, particularly given the issues relating with long-term compliance, costs and potential side effects of medical treatment. It should be noted, however, that the natural evolution of prolactinomas after menopause, a physiological state of oestrogen deficiency, has not been fully elucidated and there is indeed a scarcity of reports observing females with preexisting prolactinoma beyond the menopause without continued use of DA therapy.
Experiments in rats have shown that oophorectomy results in reduction of the size and number of lactotrophs and of the intracellular abundance of PRL-secretory granules 8 and that selective antiestrogen treatment inhibits lactotroph tumour growth in rats harbouring subcutaneously implanted PRL-secreting pituitary tumours. 9 Touraine et al 10 reported spontaneous reduction in PRL levels after menopause in 4
women with hyperprolactinaemia most likely attributed to prolactinoma. Karunkaran et al 11 in a group of 11 females with microprolactinoma followed through menopause without DA treatment, reported normalization of PRL in 45% of them; however, the duration of follow-up and the outcomes of those who remained hyperprolactinaemic are not available. Therefore, studies systematically assessing this group of patients and providing long-term outcomes and frequency of adenoma regrowth would be of value in clinical practice and would facilitate the establishment of optimal management protocols.
The aim of the present study was to investigate the natural history of prolactinoma in a series of women who have gone through menopause, who were no longer on DA therapy and were followed up in a large pituitary centre in the UK and to compare the risk of recurrence of hyperprolactinaemia of this group of patients with that of females with prolactinoma who had a trial of DA withdrawal before their menopause.
| PATIENTS AND ME THODS

| Patients
All women with the diagnosis of prolactinoma established before menopause and who after menopause were off DA treatment and were followed up in the Department of Endocrinology, Queen
Elizabeth Hospital Birmingham, UK during the period between 2000 and 2017 were studied. As a control group, we used females with prolactinoma who discontinued DA treatment before menopause and were followed up in our Department during the same time period. The patients were identified through searches by the University Hospitals Birmingham IT Services in the electronic patient record, as well as through searching the Departmental database. The diagnosis of prolactinoma was based on the detection of hyperprolactinaemia (after excluding the presence of macroprolactin and potential sec- 
| Statistics
Percentages were calculated for categorical data and medians with ranges for continuous variables. Median follow-up was 3 years (range 1-13) and was determined from the time of stopping the DA (or from the time of menopause in the 2 patients not offered DA) until the last serum PRL measurement.
| Group of women who stopped DA treatment before menopause
We identified 28 women with prolactinoma who had a trial of DA withdrawal before menopause. Their median age at diagnosis of the prolactinoma was 26 years (range 16-42), 23 had microadenoma and 5 macroadenoma, and they had received DA treatment for a median duration of 6 years (range 1-24; one of these patients had been on DA for 1 year and had chosen to stop it after achieving normal PRL) 
| Outcomes in women who stopped DA treatment after menopause
| Postmenopausal changes in serum PRL levels
Prior to stopping the DA, serum PRL was normal in 16 and above the reference range in 12 patients (Table 1) . Amongst those with (25%) ( Table 1) . Overall, at last assessment of the total group, PRL TA B L E 1 Details and outcomes of patients who stopped dopamine agonist (DA) treatment Prolactin checked between 6 and 12 months after stopping DA was normal in 9 and above the reference range in 19 patients (Table 2 ). Amongst those with normal PRL, PRL remained within normal limits in all, 9/9 (100%) at their last review. Of those with high PRL 6-12 months off DA, the last recorded review revealed that PRL had increased further in 4/18 (22%), decreased but did not normalize in 9/18 (50%) and normalized in 5/18 (28%) ( Table 2) . Overall, at last assessment of this group, PRL showed increase (with values above the reference range) in 4/27 (15%), decreased but did not normalize in 9/27 (33%) and was normal in 14/27 (52%) of the women (1 patient was excluded from these evaluations because she restarted DA within 1 year after the rise of the PRL) (Figure 2 ). Details and outcomes of the 4 patients who had further increase in serum PRL after stopping DA therapy are shown in Table 3 .
Univariate Cox regression analysis revealed that PRL levels or visible adenoma on imaging before stopping the DA, duration of treatment with DA, type of DA, and size of the tumour at diagnosis (macro-or microadenoma) were not predictors of having normal PRL at last assessment, whereas PRL values within 6-12 months after stopping DA were (HR 0.996 per mU/L, 95% CI: 0.004-0.999, P < .05).
In the 2 patients with microprolactinoma diagnosed in the perimenopausal period who had not been offered DA, serum PRL did not normalize, but decreased by 70% and 27% during observation periods of 1 and 8 years, respectively. In these patients, the lack of confirmation of prolactinoma diagnosis by demonstrating tumour shrinkage by DA treatment is a potential drawback; however, their basal PRL levels were 2920 and 1683 mU/L after having excluded secondary causes of hyperprolactinaemia.
In the total series of 30 patients, at last assessment 16 (53%) were hyperprolactinaemic.
| Prolactinoma growth
During the follow-up period, regrowth of the adenoma was detected in 2 patients (2/27, 7%) ( Table 3 ). This was not associated with pressure effects. Both had microadenomas and had shown continuous gradual increase in their PRL levels (before stopping DA: 1893 and 2500 mU/L-at last review: 6121 and 4281 mU/L, respectively).
After discussion with the patients, they were subsequently recommenced on DA. 
| Recurrence of hyperprolactinaemia after
| D ISCUSS I ON
This is the first series systematically reviewing the outcomes of females with prolactinoma who after reaching menopause had their DA treatment actively withdrawn. We found that during a median follow-up period of 3 years, 53% of the total patients had TA B L E 2 Details and outcomes of patients based on PRL levels 6-12 mo after stopping dopamine agonist (DA) treatment Adenoma visible on imaging before stopping DA n = 7/9 PRL, Prolactin. a One patient on amitriptyline (PRL 5622 mU/L) on which she was also even before stopping the DA treatment. b One patient was excluded because she restarted DA shortly after the first PRL measurement.
hyperprolactinaemia. In those previously treated with DA, this rate was 50%, with serum PRL within 6-12 months after stopping treatment being the only independent predictor. Interestingly, in 15% of the women, PRL showed an increase as compared to the levels measured between 6 and 12 months after DA withdrawal and 2 of these patients had adenoma regrowth. Our results suggest that de- In our study, the outcomes of women who had actively withdrawn DA treatment before or after menopause and were followed up during the same time period in our Department were compared.
Given that all premenopausal women had normal PRL prior stopping DA, the comparison was performed with the group of postmenopausal females who before DA withdrawal had also normal PRL. We found recurrence of hyperprolactinaemia in 31% of the postmenopausal and in 71% of the premenopausal group. After adjusting for possible confounding factors including size of adenoma at diagnosis, duration of DA treatment and visible adenoma on imaging prior DA withdrawal, we found that the risk of hyperprolactinaemia recurrence was lower in the postmenopausal group suggesting a favourable impact of menopause. Similar data comparing directly these 2 groups of women are not available and the published literature on DA withdrawal outcomes involves patients of both sexes and of any age. Thus, in a meta-analysis of studies including mainly females before menopause, the rates of persisting normoprolactinaemia after withdrawal of DA were only 21% (95% CI: 10%-37%) for micro-and 16% (95% CI: 6%-36%) for macroprolactinomas, with longer DA treatment duration associated with treatment success. 5 In a metaanalysis of reports including only patients treated with cabergoline, most of which were premenopausal females, the hyperprolactinaemia recurrence rate was 65% (95% CI: 55%-74%).
12
In comparison with the PRL values detected between 6 and 12 months after DA withdrawal, PRL decreased but remained elevated above the reference range in 33% and normalized in 52% of our patients. Although this may reflect the natural course of the tumour or the cytocidal effect of the previous DA treatment, 13 the reduction of oestrogen levels following menopause could also relate to this observation. In fact, experimental data on rats have
shown that ovariectomy has a dramatic effect on the lactotroph cells with a decrease in their size and number, as well as a reduction in the intracellular abundance of PRL secretory granules; oestradiol is the dominant ovarian hormone that reverses these effects and TA B L E 3 Details and outcomes of the patients who had further increase in the PRL values compared with those detected 6-12 mo after stopping dopamine agonist (DA) treatment subsequently stimulates PRL secretion. 8 We also found that PRL values within 6-12 months after stopping the DA were the only predictors of tumour secretory dynamics and normoprolactinaemia at last assessment providing guidance on the intensity of future surveillance and the selection of cases for possible discharge to primary care. Notably, in studies looking at predictive factors of persisting normoprolactinaemia after DA withdrawal, tumour remnant prior to DA withdrawal, longer duration of DA treatment and nadir PRL during treatment were the most commonly reported [5] [6] [7] 14 ; however, these data were derived from patient groups comprising both men and women and a wide range of ages.
Interestingly, at last assessment and, in comparison with the PRL levels detected 6-12 months after stopping DA treatment, PRL showed increase (with values above the reference range) in 4/27 (15%) of the patients (all had microadenomas at diagnosis). It is of note, that this was observed in women with high PRL levels (>2500 mU/L) measured 6-12 months after DA withdrawal (range of PRL of this group in our series 2633-4270 mU/L). During the follow-up period, regrowth of the adenoma was detected in 2 of them (7% of the total group), 4 and 6 years, after stopping the DA.
Whether the rate of adenoma regrowth would be higher if our series included more macroprolactinomas or if the follow-up was longer remains a possibility. These findings demonstrate that the growth potential of the prolactinomas remains even after menopause. In accord with this is the observation that 94% of the prolactinomas diagnosed after menopause are macroadenomas. 15 Furthermore, the long interval until detection of tumour regrowth signifies the importance of prolonged monitoring in cases with persistent hyperprolactinaemia.
It has been previously shown that the PRL levels correlate with inflammatory biomarkers 16 and that patients with untreated prolactinoma have metabolic disorders (including insulin resistance and dyslipidaemia) and an adverse cardiovascular risk profile. [17] [18] [19] [20] The significance of these findings and their potential consequences for the group of postmenopausal women with hyperprolactinaemia after DA withdrawal remain to be clarified.
A drawback of our study is the potential selection bias related to the decision on cessation DA treatment. A prospective series of nonselected, consecutive patients, who after menopause stop their DA therapy, could overcome this problem, but such a study may not be practically feasible. Furthermore, pituitary imaging was performed only in patients with gradual increase of serum PRL after treatment withdrawal. Nonetheless, given that in most of the cases PRL serves as a good marker of tumour behaviour, 21 it is unlikely that patients with adenoma regrowth may have been missed. Advantages of our study are the inclusion of subjects with systematic follow-up in the era of MRI with PRL measurements in a single laboratory (including routine macroprolactin screening) during the monitoring after DA withdrawal, and the use of a comparison group of females who stopped DA treatment before their menopause.
In conclusion, serum PRL normalizes over time in nearly half of the women with prolactinoma who pass through menopause and are not on DA treatment; serum PRL 6-12 months after DA withdrawal is a useful predictor for this and can guide clinical practice.
The risk of recurrence of hyperprolactinaemia is lower in this group compared with premenopausal women who had a trial of DA withdrawal. Nonetheless, menopause is not a sufficient condition to ensure remission of the tumour; during our follow-up period, 7% of the total group demonstrated adenoma regrowth which, given the long life expectancy after menopause, necessitates regular monitoring of the cases with persistent hyperprolactinaemia. The potential long-term consequences of the untreated hyperprolactinaemia and studies with longer follow-up on this group of patients will provide further insights on the field.
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